NasdaqCM - Nasdaq Real Time Price USD

Iterum Therapeutics plc (ITRM)

0.9598

-0.0002

(-0.02%)

At close: June 4 at 4:00:01 PM EDT

Iterum Therapeutics Announces Extension of Term of Promissory Note

DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that Pfizer Inc. (“Pfizer”) has agreed to extend the term for payment of the regulatory milestone payment of $20.0 million until October 25, 2029. “We are very pleased to announce that Pfize

GlobeNewswire 16 days ago

ITRM
-0.02%
Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ...

Iterum Therapeutics PLC (ITRM) reports reduced operating expenses and extends cash runway, while gearing up for ORLYNVAH's potential market launch.

GuruFocus.com 22 days ago

ITRM
-0.02%
Iterum Therapeutics Reports First Quarter 2025 Financial Results

--Preparing for Potential Launch of ORLYNVAHTM by Q4 2025-- --Extended Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, May 13, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2025

GlobeNewswire 22 days ago

ITRM
-0.02%
Iterum Therapeutics plc (NASDAQ:ITRM): When Will It Breakeven?

Iterum Therapeutics plc ( NASDAQ:ITRM ) is possibly approaching a major achievement in its business, so we would like...

Simply Wall St. 25 days ago

ITRM
-0.02%
Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025

DUBLIN, Ireland and CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call at 8:30 a.m. ET

GlobeNewswire 29 days ago

ITRM
-0.02%
Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

DUBLIN, Ireland and CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today closed the previously announced purchase and sale of an aggregate of 5,555,556 ordinary shares (or pre-funded warrants in lieu thereof) at a purchase price of $0.90 per ordinary share (or pre-funded war

GlobeNewswire last month

ITRM
-0.02%
Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares

DUBLIN, Ireland and CHICAGO, April 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of an aggregate of 5,555,556 ordinary shares (or pre-funded warrants in lieu ther

GlobeNewswire last month

ITRM
-0.02%
Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics

DUBLIN and CHICAGO, April 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that one poster was presented at the 35th Annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID) held in Vienna, Austria, from April 11-15, 2025. The poster presented at ECCMID was: Title:

GlobeNewswire last month

ITRM
-0.02%
Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: Navigating Financial ...

Despite FDA approval and market exclusivity for ORLYNVAH, Iterum faces strategic and financial hurdles in its commercialization efforts.

GuruFocus.com 3 months ago

ITRM
-0.02%

PFE
Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

--ORLYNVAHTM Approved by FDA in Q4 2024— --Extended Cash Runway-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31, 2024. “While outreach to pot

GlobeNewswire 3 months ago

ITRM
-0.02%
Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025

DUBLIN, Ireland and CHICAGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and full year 2024 financial results before the open of the U.S. financial markets on Friday, February 7, 2025. Management will host a conference ca

GlobeNewswire 4 months ago

ITRM
-0.02%
Iterum Therapeutics Regains Full Nasdaq Compliance

Iterum will Continue to be Listed and Traded on the Nasdaq Stock MarketDUBLIN and CHICAGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced receipt of written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC informing the Company that its defi

GlobeNewswire 6 months ago

ITRM
-0.02%
Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ...

Iterum Therapeutics PLC (ITRM) secures FDA approval for Arlinda, while navigating financial hurdles and exploring strategic options.

GuruFocus.com 6 months ago

ITRM
-0.02%

PFE
Iterum Therapeutics Reports Third Quarter 2024 Financial Results

-- ORLYNVAHTM Approved by FDA on October 25, 2024— --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2024. “With last month’s approval of

GlobeNewswire 6 months ago

ITRM
-0.02%
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

DUBLIN and CHICAGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2024 financial results before the open of the U.S. financial markets on Thursday, November 14, 2024. Management will host a conference call at 8:30 a.m. ET th

GlobeNewswire 6 months ago

ITRM
-0.02%
FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships

On Friday, Iterum Therapeutics plc (NASDAQ:ITRM) received FDA approval for its Orlynvah (sulopenem etzadroxil and probenecid) for uncomplicated urinary tract infections (uUTIs) caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options. This is the first approved indication for Orlynvah and the first FDA-approved product for Iterum. The FDA approval was based on a cli

Benzinga 7 months ago

ITRM
-0.02%
FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment

The FDA's decision was based on results from two pivotal Phase III clinical trials, SURE 1 and REASSURE.

Pharmaceutical Technology 7 months ago

ITRM
-0.02%
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

PR Newswire 7 months ago

ITRM
-0.02%
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades --Company to Host Conference Call on Monday, October 28th at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), today announced that the U.S. Food and Drug Administration (FDA) has approved Iterum’s new drug application for ORLYNVAH™ (sulopenem etzadroxil and probenecid) for the treatment of unco

GlobeNewswire 7 months ago

ITRM
-0.02%
Iterum Therapeutics to Present Data at IDWeek 2024

DUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at the Infectious Disease Society of America’s IDWeek 2024 conference taking place in Los Angeles, CA from October 16-19, 2024. Data to

GlobeNewswire 7 months ago

ITRM
-0.02%

Performance Overview

Return	ITRM	S&P 500 (^GSPC)
YTD	-45.77%	+1.52%
1-Year	-35.58%	+12.84%
3-Year	-70.92%	+45.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Iterum Therapeutics plc (ITRM)

Iterum Therapeutics Announces Extension of Term of Promissory Note

Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ...

Iterum Therapeutics Reports First Quarter 2025 Financial Results

Iterum Therapeutics plc (NASDAQ:ITRM): When Will It Breakeven?

Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025

Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares

Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics

Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: Navigating Financial ...

Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025

Iterum Therapeutics Regains Full Nasdaq Compliance

Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ...

Iterum Therapeutics Reports Third Quarter 2024 Financial Results

Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships

FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics to Present Data at IDWeek 2024

Performance Overview